Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Pulmozyme on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Pulmozyme (dornase alfa) is an inhaled enzyme therapy approved by the FDA for use in conjunction with standard therapies for the management of pediatric and adult patients with cystic fibrosis (CF), to improve pulmonary function.
Pulmozyme is a recombinant form of human deoxyribonuclease I (DNase I), an enzyme that breaks down extracellular DNA released by degenerating white blood cells in the thick, sticky mucus that accumulates in the airways of CF patients. By reducing the viscosity of this mucus, Pulmozyme helps improve airflow and reduce the frequency of respiratory infections.
Pulmozyme is intended for pediatric and adult CF patients as part of a comprehensive treatment regimen, used alongside other standard CF therapies rather than as a standalone treatment.
The typical dose is one 2.5 mg single-use ampule inhaled once daily via a recommended nebulizer; some patients may benefit from twice-daily dosing based on their treating physician's assessment.
Pulmozyme has a well-established safety profile with no formal FDA boxed warning and no significant warnings and precautions section on its label, reflecting its long history of use in cystic fibrosis management. General precautions relevant to inhaled therapies still apply.
Pulmozyme should be inhaled using a recommended nebulizer system, as different devices can affect the amount of medicine delivered to the lungs. Patients should be trained on proper inhalation technique.
As with any biologic therapy, hypersensitivity reactions are possible, though uncommon. Patients should be advised to report any unusual symptoms during or after use.
Pulmozyme is intended to be used alongside, not instead of, other standard cystic fibrosis therapies such as airway clearance techniques and other prescribed medicines.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Pulmozyme is manufactured and marketed by Genentech, Inc., a member of the Roche Group. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating pulmonologist confirming a diagnosis of cystic fibrosis. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for cystic fibrosis, Pulmozyme is sourced through authorized channels and imported under GDP-compliant, cold-chain logistics to preserve product quality throughout transit.
NPP sources Pulmozyme directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Pulmozyme must be stored refrigerated at 2°C to 8°C in its protective foil, and should not be exposed to room temperature for more than a total of 60 hours. NPP maintains a continuous, monitored cold chain throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile cold-chain logistics to the patient's city.
Patients across India can access Pulmozyme through NPP's regulated import pathway, with cystic fibrosis specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support cystic fibrosis care coordination and documentation for Pulmozyme access.
Delhi's major hospitals assist patients with prescription support and documentation for Pulmozyme.
Bangalore's specialist network offers access coordination for CF patients eligible for Pulmozyme.
Chennai-based pulmonology specialists coordinate Pulmozyme access alongside comprehensive CF care.
Hyderabad's care institutions support patients pursuing Pulmozyme therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Pulmozyme.
Pune-based specialists assist with prescription support and Pulmozyme treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Pulmozyme.
Kochi's specialist units assist patients with the documentation needed for Pulmozyme access.
Chandigarh's care centers support Pulmozyme treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Pulmozyme access process.
Lucknow-based centers assist patients pursuing Pulmozyme therapy.
Bhubaneswar's institutions support access to Pulmozyme for eligible patients.
Guwahati's specialists help coordinate Pulmozyme access for patients across the Northeast.
Patients in other cities across India can also access Pulmozyme through NPP's nationwide coordination network.
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
